Achieve Life Sciences Inc
ACHV4.460USD
+0.140+3.24%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
235.54MMarket Cap
LossP/E TTM
More Details of Achieve Life Sciences Inc Company
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
Achieve Life Sciences Inc Info
Ticker SymbolACHV
Company nameAchieve Life Sciences Inc
IPO dateOct 12, 1995
CEOStewart (Richard)
Number of employees25
Security typeOrdinary Share
Fiscal year-endOct 12
Address22722 29Th Dr. Se
CitySEATTLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98021
Phone14256861500
Websitehttps://achievelifesciences.com/
Ticker SymbolACHV
IPO dateOct 12, 1995
CEOStewart (Richard)
Company Executives of Achieve Life Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark K. Oki
Mr. Mark K. Oki
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
127.94K
+1179.40%
Ms. Jaime Xinos
Ms. Jaime Xinos
Chief Commercial Officer
Chief Commercial Officer
74.44K
+183.11%
Mr. Thomas B. King
Mr. Thomas B. King
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
--
--
Mr. Richard Stewart
Mr. Richard Stewart
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Nancy R. Phelan
Ms. Nancy R. Phelan
Independent Director
Independent Director
--
--
Dr. Kristen B. Slaoui, Ph.D.
Dr. Kristen B. Slaoui, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas Sellig
Mr. Thomas Sellig
Independent Director
Independent Director
--
--
Ms. Nicole Jones
Ms. Nicole Jones
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark K. Oki
Mr. Mark K. Oki
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
127.94K
+1179.40%
Ms. Jaime Xinos
Ms. Jaime Xinos
Chief Commercial Officer
Chief Commercial Officer
74.44K
+183.11%
Mr. Thomas B. King
Mr. Thomas B. King
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
--
--
Mr. Richard Stewart
Mr. Richard Stewart
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Nancy R. Phelan
Ms. Nancy R. Phelan
Independent Director
Independent Director
--
--
Dr. Kristen B. Slaoui, Ph.D.
Dr. Kristen B. Slaoui, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Simplify Asset Management Inc
9.34%
Franklin Advisers, Inc.
8.38%
The Vanguard Group, Inc.
4.62%
Propel Bio Management, LLC
4.38%
Contrarian Alpha Management, L.L.C.
3.14%
Other
70.14%
Shareholders
Shareholders
Proportion
Simplify Asset Management Inc
9.34%
Franklin Advisers, Inc.
8.38%
The Vanguard Group, Inc.
4.62%
Propel Bio Management, LLC
4.38%
Contrarian Alpha Management, L.L.C.
3.14%
Other
70.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.28%
Investment Advisor/Hedge Fund
12.46%
Hedge Fund
5.27%
Individual Investor
4.94%
Venture Capital
4.55%
Research Firm
1.46%
Family Office
0.94%
Bank and Trust
0.08%
Pension Fund
0.05%
Other
49.96%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
160
23.50M
57.38%
+125.00K
2025Q3
164
23.37M
60.39%
-6.77M
2025Q2
155
30.14M
37.30%
+11.84M
2025Q1
143
18.31M
55.82%
-1.05M
2024Q4
139
23.71M
68.36%
-640.94K
2024Q3
132
24.78M
74.65%
-1.66M
2024Q2
119
26.41M
68.20%
+2.24M
2024Q1
94
24.17M
34.41%
+12.39M
2023Q4
81
8.11M
45.80%
-389.63K
2023Q3
79
8.50M
46.11%
-452.11K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Simplify Asset Management Inc
1.18M
2.32%
+966.67K
+443.74%
Jun 30, 2025
Franklin Advisers, Inc.
4.46M
8.73%
+2.00M
+81.34%
Jun 30, 2025
The Vanguard Group, Inc.
2.15M
4.21%
+432.86K
+25.21%
Jun 30, 2025
Propel Bio Management, LLC
9.85M
19.28%
+7.40M
+301.66%
Jun 30, 2025
Contrarian Alpha Management, L.L.C.
1.54M
3.02%
+105.00K
+7.30%
May 15, 2024
Patrick (Callahan J. III)
1.53M
2.99%
--
--
Apr 15, 2025
Nantahala Capital Management, LLC
898.88K
1.76%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
362.20K
0.71%
-406.77K
-52.90%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
8.96%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Simplify Propel Opportunities ETF
Proportion8.96%
iShares Micro-Cap ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Date
Type
Ratio
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
FAQs
Who are the top five shareholders of Achieve Life Sciences Inc?
The top five shareholders of Achieve Life Sciences Inc are:
Simplify Asset Management Inc holds 1.18M shares, accounting for 2.32% of the total shares.
Franklin Advisers, Inc. holds 4.46M shares, accounting for 8.73% of the total shares.
The Vanguard Group, Inc. holds 2.15M shares, accounting for 4.21% of the total shares.
Propel Bio Management, LLC holds 9.85M shares, accounting for 19.28% of the total shares.
Contrarian Alpha Management, L.L.C. holds 1.54M shares, accounting for 3.02% of the total shares.
Simplify Asset Management Inc holds 1.18M shares, accounting for 2.32% of the total shares.
Franklin Advisers, Inc. holds 4.46M shares, accounting for 8.73% of the total shares.
The Vanguard Group, Inc. holds 2.15M shares, accounting for 4.21% of the total shares.
Propel Bio Management, LLC holds 9.85M shares, accounting for 19.28% of the total shares.
Contrarian Alpha Management, L.L.C. holds 1.54M shares, accounting for 3.02% of the total shares.
What are the top three shareholder types of Achieve Life Sciences Inc?
The top three shareholder types of Achieve Life Sciences Inc are:
Simplify Asset Management Inc
Franklin Advisers, Inc.
The Vanguard Group, Inc.
Simplify Asset Management Inc
Franklin Advisers, Inc.
The Vanguard Group, Inc.
How many institutions hold shares of Achieve Life Sciences Inc (ACHV)?
As of 2025Q4, 160 institutions hold shares of Achieve Life Sciences Inc, with a combined market value of approximately 23.50M, accounting for 57.38% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.01%.
What is the biggest source of revenue for Achieve Life Sciences Inc?
In --, the -- business generated the highest revenue for Achieve Life Sciences Inc, amounting to -- and accounting for --% of total revenue.
